Daiichi completes Ranbaxy buy, seeks "to realize sustainable growth"

Singh will also be a part of Daiichi's senior global management team, he added.

"We are pleased to announce that all the planned transactions of this landmark deal have been successfully completed. We are determined to work with Ranbaxy to realize sustainable growth," said Takashi Shoda, president and CEO, Daiichi Sankyo.

"We are pleased that the deal has been closed successfully. This puts us well on the path to create a hybrid business model that will unlock the strengths of both companies to bring unprecedented value to all stakeholders," said Malvinder Mohan Singh, CEO and managing director, Ranbaxy Laboratories.

"We expect to assimilate the available synergies of both partners to exponentially enhance the overall scope, scale and effectiveness of the business," Singh said.

The funds, Ranbaxy said in a statement, will be used to drive the company's growth through organic and inorganic means while significantly strengthening its balance sheet.